JMP Securities Downgrades Arbutus Biopharma (ABUS) to Market Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Wall St futures rise ahead of jobs report as bond market steadies, oil slips
- U.S. economy adds 29,000 jobs in September
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- BofA's Hartnett sees risk-off mood lasting until dollar peaks
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
Wedbush Downgrades Arbutus Biopharma (ABUS) to Underperform
October 9, 2018 10:10 AM EDTWedbush analyst Robert Driscoll downgraded Arbutus Biopharma (NASDAQ: ABUS) from Neutral to Underperform with a price target of $5.00 (from $7.00).
For an analyst ratings summary and ratings history on Arbutus Biopharma click here. For more ratings news on Arbutus Biopharma click here.
Shares of Arbutus Biopharma closed at $9.09 yesterday.
... More